Danaher Corporation

DHR Healthcare Diagnostics & Research

Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.

228.97 2.53 −1.09%
Market cap
$162.7B
P/E
40.5×
Fwd P/E
29.2×
Dividend yield
0.66%
F-score
6/9
Altman Z
4.52
Beneish M
−2.57
Dividend safety
69/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
7.63% 7.11% 7.08% 6.84%

+8 more TTM periods

Piotroski F-Score
6 6 6 7
ROA
4.60% 4.54% 4.49% 4.36%
ROIC
4.37% 4.59% 4.42% 4.34%
Return on Tangible Assets
36.07% 30.89% 31.48% 40.46%
Average Days of Receivables
57.64 56.26 58.13 56.48
Free Cash Flow per Share
7.78 7.51 7.43 7.07
Free Cash Flow
5,489.00 5,318.00 5,293.00 5,028.00
Capital Expenditures
(1,146.00) (1,121.00) (1,123.00) (1,290.00)
Other line items
Cash ROIC
6.69% 6.98% 7.00% 7.24%
Accounts Receivable Turnover
6.67 6.77 6.60 6.68
Accounts Payable Turnover
5.87 5.79 5.59 5.96
Inventory Turnover
3.50 3.96 4.17 3.67
Average Days of Payables
63.85 64.21 67.00 63.11
Days of Inventory on Hand
114.24 93.55 90.44 99.38
Tax Rate
(0.16) (0.15) (0.15) (0.16)
Research and Development Expense of Revenue
6.43% 6.48% 6.50% 6.60%
Selling, General and Administrative Expense of Revenue
31.66% 33.24% 33.52% 33.92%
Share Based Compensation of Revenue
1.18% 1.19% 1.21% 1.20%
Interest Coverage
17.56 18.59 17.70 17.02
Operating CF/Net income
1.66 1.75 1.78 1.80
Depreciation/Fixed assets
0.44 0.45 0.44 0.45
Capex/Depreciation
(0.44) (0.45) (0.46) (0.53)
Revenue per Share
35.60 35.00 34.47 34.15
Operating CF per Share
9.41 9.10 9.00 8.89
Capex per Share
(1.62) (1.58) (1.58) (1.82)
Capex to Sales
0.05 0.05 0.05 0.05

Fold the line items

Columns are period end dates